Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices
26 6월 2023 - 9:25PM
Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage
pharmaceutical company focused on the development and
commercialization of therapies for patients with rare genetic
mitochondrial diseases, today announced that it has been added to
the broad-market Russell 3000® Index at the conclusion of the 2023
Russell indexes annual reconstitution, effective after the US
market opens on June 26, according to a preliminary list of
additions posted May 19.
Annual Russell indexes reconstitution captures
the 4,000 largest US stocks as of April 28, 2023, ranking them by
total market capitalization. Membership in the US all-cap Russell
3000® Index, which remains in place for one year, means automatic
inclusion in the large-cap Russell 1000® Index or small-cap Russell
2000® Index as well as the appropriate growth and value style
indexes. FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings and style
attributes.
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $12.1
trillion in assets are benchmarked against Russell’s US indexes.
Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell 3000® Index
and the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the
development and commercialization of therapies for patients with
rare genetic mitochondrial diseases, which are often associated
with the inability of mitochondria to produce adenosine
triphosphate (ATP). Our lead product candidate, mavodelpar, is a
potent and selective agonist of the peroxisome
proliferator-activated receptor delta (PPARδ). Mavodelpar has been
shown to increase transcription of genes involved in mitochondrial
function and increase fatty acid oxidation (FAO), and may increase
production of new mitochondria. For additional information, please
see reneopharma.com.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative
benchmarking, analytics and data solutions for investors worldwide.
FTSE Russell calculates thousands of indexes that measure and
benchmark markets and asset classes in more than 70 countries,
covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately $20.1
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create ETFs, structured products
and index-based derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com.
Contacts:
Danielle SpanglerInvestor RelationsReneo Pharmaceuticals,
Inc.dspangler@reneopharma.com
Matthew Purcell, Pharm.D.Media InquiriesRusso Partners,
LLCmatthew.purcell@russopartnersllc.com
Reneo Pharmaceuticals (NASDAQ:RPHM)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Reneo Pharmaceuticals (NASDAQ:RPHM)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024